AI assistant
Q32 Bio Inc. — Director's Dealing 2018
Sep 27, 2018
34891_dirs_2018-09-27_084309d4-f052-40e3-8938-7e99ecfe549f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Homology Medicines, Inc. (FIXX)
CIK: 0001661998
Period of Report: 2018-09-20
Reporting Person: Kelly Timothy P (See Remarks)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Employee Stock Options | $2.8947 | 2027-09-06 | Common Stock (38001) | Direct | |
| Employee Stock Option | $6.6314 | 2027-12-06 | Common Stock (47500) | Direct | |
| Employee Stock Option | $16.00 | 2028-03-26 | Common Stock (95002) | Direct |
Footnotes
F1: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in equal monthly installments over a three year period thereafter. The vesting commencement date for this option was May 30, 2017.
F2: The option vests and becomes exercisable upon the Reporting Person's completion of each full month of service after January 1, 2018, so that such option will become fully vested on January 1, 2022.
F3: The option vests and becomes exercisable in 48 equal monthly installments on the first day of each calendar month following March 27, 2018.